IMPORTANT FDA ADVISORY

In view of the recent FDA memo entitled, "Changes in Package Insert regarding Safety," and in keeping with The Oncologist's policy, the CME availability for recently published papers dealing with zoledronic acid (Zometa) has been suspended. This does not in any way interrupt the reading of the full papers online; it only pertains to their CME availability. These papers are being re-reviewed by the appropriate CME committee whose decisions regarding accreditation will be announced when their review is complete.


For further information, please see:

• FDA Letter of January 31, 2005  Click here to read
• Dr. Richard Pazdur's Memo of February 7, 2005  Click here to read